Finasteride Tablet, Film Coated
Product Images NDC 71335-1530

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 71335-1530). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 Symptom Score In A Long-term Efficacy And Safety Study (Finasteride Fig1)

A line graph titled "Symptom Score in a Long-Term Efficacy and Safety Study" showing mean change from baseline symptom scores over four years. It compares two groups: one receiving Finasteride and the other a placebo. The y-axis represents mean change from baseline ± 1 standard error, and the x-axis covers baseline through Year 4. Finasteride shows a greater decrease in symptom scores over time compared to placebo, with sample sizes noted for each time point.*

FDA Label Image

Figure 2 Percent Of Patients Having Surgery For Bph, Including Turp (Finasteride Fig2)

A line graph titled 'Percent of Patients Having Surgery for BPH, Including TURP' comparing Finasteride versus placebo groups over 48 months. The y-axis shows percent of patients from 0% to 15%, and the x-axis shows observation time in months. Finasteride group shows a lower percentage of patients undergoing surgery compared to placebo. Below the graph is a table listing cumulative number of events and number at risk per year for both groups.*

FDA Label Image

Figure 3 (Finasteride Fig3)

A line chart titled 'Percent of Patients Developing Acute Urinary Retention (Spontaneous and Precipitated)' showing cumulative incidence over 48 months. The chart compares two groups: Finasteride and Placebo. The X-axis shows observation time in months, and the Y-axis shows percent of patients up to 15%. The Placebo group shows a higher percent of patients developing acute urinary retention compared to the Finasteride group over time. Below the chart, cumulative event numbers and patients at risk per year are tabulated for both groups.*

FDA Label Image

Figure 4 (Finasteride Fig4)

A line graph titled 'Prostate Volume in a Long-Term Efficacy and Safety Study' showing mean percent change from baseline with standard error bars over four years. The x-axis represents time points from baseline to year 4, and the y-axis represents mean percent change from baseline. Two data series are shown: placebo (circles) displaying an increasing trend, and finasteride (squares) showing a decreasing trend in prostate volume over time. Sample sizes for each group at each time point are listed below the graph.*

FDA Label Image

Figure 5 (Finasteride Fig5)

A line graph titled 'Cumulative Incidence of a 4-Point Rise in AUA Symptom Score by Treatment Group' showing percent with event on the Y-axis and years from randomization on the X-axis. It compares four groups: Placebo, Finasteride, Doxazosin, and Combination over a period of 5.5 years, illustrating the cumulative incidence trends for each treatment group.*

FDA Label Image

Chemical Structure (Finasteride Str)

Chemical structure of Finasteride, a synthetic compound with multiple ring systems and functional groups, depicted in a skeletal formula drawing.*

FDA Label Image

Label Image (Lbl713351530)

Finasteride 5 mg tablet label from Bryant Ranch Prepack. The label specifies the product as a blue round tablet, compares it to Proscar 5 mg tablet by Rising Health LLC, and states storage conditions of 20°-25°C (68°-77°F). The label shows a package count of 100 tablets, an NDC number 71335-1530-1, a lot number 1523487, and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.